vasopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
vasoconstrictors, vasopressin derivatives 2810 113-79-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vasopressin
  • 8-L-arginine vasopressin
  • synthetic vasopressin
  • 8-L-Arginine-vasopressin
  • argipressin
  • vasopressin tannate
  • vasopressin injection
  • antidiuretic hormone
  • pitressin tannate
  • Molecular weight: 1084.24
  • Formula: C46H65N15O12S2
  • CLOGP: -2.31
  • LIPINSKI: 3
  • HAC: 27
  • HDO: 15
  • TPSA: 461.43
  • ALOGS: -3.93
  • ROTB: 19

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 U P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI

Approvals:

DateAgencyCompanyOrphan
None FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 102.91 35.88 102 3381 235367 50366274
Cardiogenic shock 102.39 35.88 39 3444 15560 50586081
Drug ineffective 102.34 35.88 192 3291 819141 49782500
Intentional overdose 97.60 35.88 58 3425 62446 50539195
Cardiac arrest 96.39 35.88 64 3419 83587 50518054
Shock 95.13 35.88 40 3443 20610 50581031
Metabolic acidosis 90.72 35.88 47 3436 38778 50562863
Multiple organ dysfunction syndrome 89.94 35.88 51 3432 50286 50551355
Septic shock 89.10 35.88 53 3430 57122 50544519
Pulseless electrical activity 86.97 35.88 28 3455 6813 50594828
Acute kidney injury 71.58 35.88 83 3400 227975 50373666
Lactic acidosis 65.55 35.88 36 3447 33319 50568322
Local anaesthetic systemic toxicity 61.58 35.88 13 3470 599 50601042
Toxicity to various agents 56.26 35.88 71 3412 212428 50389213
Diabetes insipidus 48.56 35.88 14 3469 2350 50599291
Disseminated intravascular coagulation 46.57 35.88 23 3460 17112 50584529
Respiratory failure 44.30 35.88 42 3441 91139 50510502
Vasoplegia syndrome 43.72 35.88 11 3472 1103 50600538
Pulmonary oedema 43.53 35.88 32 3451 48906 50552735
Circulatory collapse 43.21 35.88 23 3460 19977 50581664
Hypothermia 41.43 35.88 19 3464 11997 50589644
Peripheral ischaemia 40.39 35.88 14 3469 4262 50597379
Acute respiratory distress syndrome 39.31 35.88 22 3461 21077 50580564
Haemodynamic instability 38.45 35.88 16 3467 8008 50593633
Bradycardia 37.79 35.88 33 3450 64393 50537248
Ventricular tachycardia 36.46 35.88 19 3464 15802 50585839

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 304.75 38.29 78 4899 3402 29566148
Cardiogenic shock 278.94 38.29 109 4868 19081 29550469
Multiple organ dysfunction syndrome 275.94 38.29 156 4821 62960 29506590
Appendicitis 233.45 38.29 78 4899 8701 29560849
Stress 219.96 38.29 95 4882 21395 29548155
Drug ineffective 193.69 38.29 268 4709 362902 29206648
Ascites 144.85 38.29 85 4892 36534 29533016
Diabetes insipidus 130.17 38.29 37 4940 2397 29567153
Sepsis 126.89 38.29 137 4840 142545 29427005
Abdominal distension 122.36 38.29 83 4894 45828 29523722
Hyponatraemia 103.97 38.29 88 4889 67545 29502005
General physical health deterioration 88.13 38.29 97 4880 102760 29466790
Ventricular fibrillation 79.42 38.29 43 4934 15790 29553760
Vasoplegia syndrome 59.00 38.29 18 4959 1490 29568060
Abdominal pain 56.90 38.29 90 4887 135267 29434283
Constipation 52.27 38.29 79 4898 114081 29455469
Serotonin syndrome 47.35 38.29 32 4945 17480 29552070
Renal injury 46.43 38.29 26 4951 10176 29559374
Hypotension 46.06 38.29 101 4876 194253 29375297
Lactic acidosis 45.62 38.29 39 4938 30208 29539342
Respiratory failure 45.55 38.29 68 4909 97063 29472487
Metabolic acidosis 43.89 38.29 42 4935 37620 29531930
Off label use 42.92 38.29 129 4848 300671 29268879
Fear 42.65 38.29 24 4953 9480 29560070
Septic shock 41.76 38.29 52 4925 62508 29507042
Drug ineffective for unapproved indication 40.89 38.29 27 4950 14187 29555363
Cardiac arrest 38.80 38.29 59 4918 85532 29484018

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiogenic shock 367.17 28.86 144 8402 32283 64457903
Multiple organ dysfunction syndrome 342.00 28.86 195 8351 101218 64388968
Appendicolith 323.27 28.86 78 8468 3391 64486795
Drug ineffective 278.26 28.86 437 8109 839810 63650376
Appendicitis 218.21 28.86 78 8468 13491 64476695
Diabetes insipidus 171.97 28.86 50 8496 4471 64485715
Stress 153.28 28.86 97 8449 60437 64429749
Sepsis 148.46 28.86 167 8379 230174 64260012
Ascites 136.46 28.86 91 8455 61910 64428276
Metabolic acidosis 123.09 28.86 90 8456 70868 64419318
Hypotension 112.13 28.86 189 8357 380785 64109401
Vasoplegia syndrome 106.98 28.86 31 8515 2736 64487450
Cardiac arrest 103.01 28.86 114 8432 153950 64336236
Lactic acidosis 99.98 28.86 75 8471 61335 64428851
Ventricular fibrillation 99.73 28.86 53 8493 23807 64466379
Septic shock 99.55 28.86 94 8452 105343 64384843
Intentional overdose 90.30 28.86 83 8463 89861 64400325
Abdominal distension 89.49 28.86 85 8461 95909 64394277
Shock 88.62 28.86 58 8488 38182 64452004
Pulseless electrical activity 85.23 28.86 39 8507 12700 64477486
Acute kidney injury 84.10 28.86 184 8362 449056 64041130
Respiratory failure 82.39 28.86 104 8442 161079 64329107
Hyponatraemia 81.09 28.86 99 8447 148240 64341946
Fatigue 66.73 28.86 10 8536 748720 63741466
Acute respiratory distress syndrome 64.33 28.86 48 8498 38887 64451299
General physical health deterioration 63.35 28.86 104 8442 204321 64285865
Haemodynamic instability 59.14 28.86 32 8514 14880 64475306
Serotonin syndrome 57.37 28.86 45 8501 39237 64450949
Local anaesthetic systemic toxicity 51.64 28.86 13 8533 672 64489514
Drug ineffective for unapproved indication 50.57 28.86 38 8508 31095 64459091
Peripheral ischaemia 47.85 28.86 23 8523 8355 64481831
Renal injury 47.36 28.86 28 8518 15401 64474785
Headache 47.26 28.86 7 8539 529460 63960726
Dizziness 45.33 28.86 3 8543 430160 64060026
Renal failure 44.01 28.86 83 8463 181605 64308581
Off label use 42.69 28.86 181 8365 632625 63857561
Toxicity to various agents 41.77 28.86 124 8422 363389 64126797
Arthralgia 41.46 28.86 5 8541 442255 64047931
Pulse absent 40.57 28.86 21 8525 8925 64481261
Electrocardiogram QRS complex prolonged 39.92 28.86 21 8525 9223 64480963
Circulatory collapse 39.51 28.86 34 8512 33698 64456488
Acidosis 38.80 28.86 26 8520 17769 64472417
Disseminated intravascular coagulation 38.69 28.86 33 8513 32315 64457871
Bradycardia 37.72 28.86 61 8485 118158 64372028
Overdose 37.52 28.86 72 8474 159494 64330692
Rash 36.70 28.86 8 8538 458541 64031645
Malaise 33.62 28.86 6 8540 396241 64093945
Fear 33.60 28.86 25 8521 20146 64470040
Ventricular tachycardia 33.13 28.86 31 8515 34234 64455952
Heparin-induced thrombocytopenia 33.07 28.86 18 8528 8461 64481725
Intestinal ischaemia 32.96 28.86 20 8526 11529 64478657
Diarrhoea 32.38 28.86 29 8517 722675 63767511
Anhedonia 32.24 28.86 21 8525 13685 64476501
Ischaemic hepatitis 31.75 28.86 13 8533 3233 64486953
Compartment syndrome 31.62 28.86 14 8532 4218 64485968
Abdominal pain 31.61 28.86 102 8444 312273 64177913
Renal tubular necrosis 31.56 28.86 25 8521 22085 64468101
Distributive shock 30.95 28.86 11 8535 1864 64488322
Dyspnoea 30.82 28.86 30 8516 718644 63771542
Hyperdynamic left ventricle 29.45 28.86 7 8539 284 64489902
Burkholderia test positive 29.26 28.86 8 8538 571 64489615

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01BA01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
POSTERIOR PITUITARY LOBE HORMONES
Vasopressin and analogues
FDA CS M0022562 Vasopressins
FDA PE N0000009908 Vasoconstriction
FDA PE N0000175360 Decreased Diuresis
MeSH PA D050034 Antidiuretic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
MeSH PA D045283 Natriuretic Agents
MeSH PA D014662 Vasoconstrictor Agents
CHEBI has role CHEBI:35554 cardiovascular agent
CHEBI has role CHEBI:50248 hematologic agents
CHEBI has role CHEBI:52290 mitogens

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nocturnal enuresis indication 8009008
Hereditary factor VIII deficiency disease indication 28293008 DOID:12134
von Willebrand disorder indication 128105004 DOID:12531
Partial Central Diabetes Insipidus indication
Cardiac arrest off-label use 410429000 DOID:0060319
Uremic Bleeding Tendency off-label use
Chronic glomerulonephritis contraindication 20917003
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Uremia contraindication 44730006 DOID:4676
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Asthma contraindication 195967001 DOID:2841
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.19 acidic
pKa3 12.56 acidic
pKa4 12.85 acidic
pKa5 13.19 acidic
pKa6 13.43 acidic
pKa7 13.76 acidic
pKa8 10.75 Basic
pKa9 6.4 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9375478 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9687526 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9744209 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9744239 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9937223 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9375478 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9687526 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9744209 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9744239 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
20UNITS/ML (20UNITS/ML) VASOPRESSIN EAGLE PHARMS A211538 Dec. 15, 2021 RX SOLUTION INTRAVENOUS July 17, 2022 PATENT CHALLENGE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vasopressin V1a receptor GPCR AGONIST Ki 9.59 CHEMBL CHEMBL
Vasopressin V1b receptor GPCR AGONIST Ki 9.31 CHEMBL CHEMBL
Vasopressin V2 receptor GPCR AGONIST Ki 8.92 CHEMBL CHEMBL
Oxytocin receptor GPCR Ki 8.78 CHEMBL
Vasopressin V2 receptor GPCR IC50 8.48 CHEMBL
Oxytocin receptor GPCR Ki 8.93 CHEMBL
Vasopressin V2 receptor GPCR Ki 9.35 CHEMBL
Vasopressin V2 receptor GPCR Kd 8.82 CHEMBL
Vasopressin V1a receptor GPCR Kd 9.19 CHEMBL
Vasopressin V1b receptor GPCR Ki 9.54 CHEMBL
Vasopressin V1 receptor GPCR Kd 9.19 CHEMBL

External reference:

IDSource
4018654 VUID
N0000179795 NUI
D00101 KEGG_DRUG
4018654 VANDF
C1705480 UMLSCUI
CHEBI:9937 CHEBI
CHEMBL373742 ChEMBL_ID
CHEMBL2108986 ChEMBL_ID
DB00067 DRUGBANK_ID
2168 IUPHAR_LIGAND_ID
C016671 MESH_SUPPLEMENTAL_RECORD_UI
Y4907O6MFD UNII
644077 PUBCHEM_CID
1098 RXNORM
3144 MMSL
5667 MMSL
d00398 MMSL
002122 NDDF
002123 NDDF
002126 NDDF
005438 NDDF
005439 NDDF
126192003 SNOMEDCT_US
421078009 SNOMEDCT_US
772208008 SNOMEDCT_US
77671006 SNOMEDCT_US
CHEMBL1201528 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 0517-1020 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 25 sections
VASOPRESSIN HUMAN PRESCRIPTION DRUG LABEL 1 42367-570 INJECTION 20 U PARENTERAL ANDA 24 sections